PubMed

Cost-effectiveness of detecting and treating diabetic retinopathy.

Javitt JC, Aiello LP.

Ann Intern Med. 1996 Jan 1;124(1 Pt 2):164-9.PMID: 8554212 [PubMed - indexed for MEDLINE]Related articles

Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform.

Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S.

Diabetes Care. 1994 Aug;17(8):909-17.PMID: 7956643 [PubMed - indexed for MEDLINE]Related articles

Cost savings associated with detection and treatment of diabetic eye disease.

Javitt JC.

Pharmacoeconomics. 1995;8 Suppl 1:33-9.PMID: 10159001 [PubMed - indexed for MEDLINE]Related articles

Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.

Vijan S, Hofer TP, Hayward RA.

JAMA. 2000 Feb 16;283(7):889-96.PMID: 10685713 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.

[No authors listed]

JAMA. 1998 Nov 25;280(20):1757-63. Erratum in: JAMA 1999 Jan 27;281(4):325. PMID: 9842951 [PubMed - indexed for MEDLINE]Related articlesFree article

Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia.

Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M.

Diabetes Care. 1997 May;20(5):735-44.PMID: 9135935 [PubMed - indexed for MEDLINE]Related articles

Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology.

Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK.

Ophthalmology. 1991 Oct;98(10):1565-73; discussion 1574.PMID: 1961646 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy.

Polak BC, Crijns H, Casparie AF, Niessen LW.

Health Policy. 2003 Apr;64(1):89-97.PMID: 12644331 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of current approaches to the control of retinopathy in type I diabetics.

Javitt JC, Canner JK, Sommer A.

Ophthalmology. 1989 Feb;96(2):255-64.PMID: 2495499 [PubMed - indexed for MEDLINE]Related articles

Continuous computer simulation analysis of the cost-effectiveness of screening and treating diabetic retinopathy.

Crijns H, Casparie AF, Hendrikse F.

Int J Technol Assess Health Care. 1999 Winter;15(1):198-206.PMID: 10407606 [PubMed - indexed for MEDLINE]Related articles

The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

Huang ES, Shook M, Jin L, Chin MH, Meltzer DO.

Diabetes Care. 2006 Feb;29(2):259-64.PMID: 16443870 [PubMed - indexed for MEDLINE]Related articlesFree article

Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.

Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M.

Ann Intern Med. 2004 May 4;140(9):689-99.PMID: 15126252 [PubMed - indexed for MEDLINE]Related articlesFree article

Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan.

Tung TH, Shih HC, Chen SJ, Chou P, Liu CM, Liu JH.

J Epidemiol. 2008;18(5):225-33. Epub 2008 Sep 8.PMID: 18776707 [PubMed - indexed for MEDLINE]Related articlesFree article

Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model.

Javitt JC, Canner JK, Frank RG, Steinwachs DM, Sommer A.

Ophthalmology. 1990 Apr;97(4):483-94; discussion 494-5.PMID: 2109299 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

CDC Diabetes Cost-effectiveness Group.

JAMA. 2002 May 15;287(19):2542-51.PMID: 12020335 [PubMed - indexed for MEDLINE]Related articlesFree article

Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis.

Maberley D, Walker H, Koushik A, Cruess A.

CMAJ. 2003 Jan 21;168(2):160-4.PMID: 12538543 [PubMed - indexed for MEDLINE]Related articlesFree article

Retinopathy screening in individuals with type 2 diabetes: who, how, how often, and at what cost--an epidemiologic review.

Swanson M.

Optometry. 2005 Nov;76(11):636-46. Review.PMID: 16298316 [PubMed - indexed for MEDLINE]Related articles

A cost analysis of community screening for diabetes in the central Wisconsin Medicare population (results from the MetaStar pilot project in Wausau).

Lee DS, Remington P, Madagame J, Blustein J.

WMJ. 2000 Jun;99(3):39-43.PMID: 10927980 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.

Brändle M, Azoulay M, Greiner RA.

Int J Clin Pharmacol Ther. 2007 Apr;45(4):203-20.PMID: 17474539 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM.

Pharmacoeconomics. 2004;22(15):1015-27.PMID: 15449965 [PubMed - indexed for MEDLINE]Related articles